ACE2 and COVID-19: Following clinical trials, their ACE2:B0AT1-screened choice of BNT162b2 mRNA2 was approved by US FDA for emergency use authorization delivery by lipid nanoparticles as the country's first publicly deployed COVID-19 vaccine.